Showing 2131-2140 of 5643 results for "".
- National Eye Institute Study Revisits Role of Annexin-V Biomarker in Retinal Cell Degenerationhttps://modernod.com/news/national-eye-institute-study-revisits-role-of-annexin-v-biomarker-in-retinal-cell-degeneration/2482588/Recent findings from a National Eye Institute-led study shed new light on annexin-V, a widely used biomarker to track apoptosis and retinal cell death in eye disease. The study group identified that annexin-V also binds to immune cells, suggesting it may a have a role as a marker for ocular infla
- Emmecell Announces Advancements of Non-Surgical Cell Therapy for Corneal Edemahttps://modernod.com/news/emmecell-announces-advancements-of-non-surgical-cell-therapy-for-corneal-edema/2482551/Emmecell announced positive results from its US multicenter phase 1 trial evaluating EO2002, a non-surgical cell therapy for corneal edema. The randomized, double-masked trial showed significant improvement in patients’ best corrected visual acuity (BCVA), reduction in central cor
- Alkeus Secures Rare Pediatric Disease and Fast Track FDA Designations for Gildeuretinol in Stargardt Diseasehttps://modernod.com/news/alkeus-secures-rare-pediatric-disease-and-fast-track-fda-designations-for-gildeuretinol-in-stargardt-disease/2482549/Alkeus Pharmaceuticals announced that its investigational oral therapy, gildeuretinol (ALK-001), has been granted Rare Pediatric Disease and Fast Track designations by the FDA for the treatment of Stargardt disease. “Stargardt disease imposes a relentless burden, robbing chil
- FELIQS Receives FDA Fast Track Designation for FLQ-101, a First-in-Class Small Molecule to Prevent Retinopathy of Prematurityhttps://modernod.com/news/feliqs-receives-fda-fast-track-designation-for-flq-101-a-first-in-class-small-molecule-to-prevent-retinopathy-of-prematurity/2482526/FELIQS announced that the US Food and Drug Administration (FDA) has granted its lead asset, FLQ-101, Fast Track designation for the prevention of retinopathy of prematurity (ROP). The company plans to conduct a Phase1b/2 study of FLQ-101 (tROPhy-1 study) both in the United States and Ja
- Study of Alkeus' Oral Gildeuretinol Demonstrate Trend in Slowing GA Progression and Visual Function Improvementhttps://modernod.com/news/study-of-alkeus-oral-gildeuretinol-demonstrate-significant-trend-in-slowing-ga-progression-and-visual-function-improvement/2482511/Alkeus Pharmaceuticals announced findings from its SAGA study, which evaluated the investigational oral therapy gildeuretinol (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study showed a statistically significant reduction in GA l
- Life Biosciences Presents New Data on Novel Gene Therapy at AAOhttps://modernod.com/news/life-biosciences-presents-new-data-on-novel-gene-therapy-at-aao/2482505/Life Biosciences announced new data at the 2024 American Association of Ophthalmology (AAO) annual meeting on its gene therapy for optic neuropathies. According to Life Biosciences, the data replicates earlier findings in nonhuman primates (NHPs) and provides insights into the dosing and tim
- SpyGlass Pharma Unveils Promising 18-Month Data from First-in-Human Study of Glaucoma Drug Delivery Platformhttps://modernod.com/news/spyglass-pharma-unveils-promising-18-month-data-from-first-in-human-study-of-glaucoma-drug-delivery-platform/2482500/SpyGlass Pharma presented 18-month follow-up data today from its first-in-human study of patients with glaucoma or ocular hypertension. The study evaluated the efficacy of the SpyGlass IOL-based drug delivery platform, which was implanted during cataract surgery. The results were shared at Eyecel
- Haag-Streit to Host "Biometry Focus Month 2024" with Weekly Webinars in Novemberhttps://modernod.com/news/haag-streit-to-host-biometry-focus-month-2024-with-weekly-webinars-in-november/2482492/Haag-Streit has announced the return of "Biometry Focus Month 2024" in November. The event will feature a series of live webinars every Thursday from November 7 to November 28, 2024. Each session will address critical topics in biometry, offering cataract and refractive surgeons ke
- Ophthalmic Drug Delivery Summit to Convene in San Franciscohttps://modernod.com/news/ophthalmic-drug-delivery-summit-to-convene-in-san-francisco/2482481/In January, over 60 world-leading specialists in ophthalmic drug delivery will gather in San Francisco for the 3rd annual Ophthalmic Drug Delivery Summit, an industry-focused event dedicated to enhancing the effectiveness, durability, and minimally invasive nature of retinal drug delivery.</
- Zeiss Launches Micor 700 Lens Extraction Devicehttps://modernod.com/news/zeiss-launches-micor-700-lens-extraction-device/2482459/Zeiss announced the US launch of the Micor 700 lens extraction device, which is designed to eliminate the need for ultrasound, offering a more sustainable and cost-effective solution while expanding the intraocular working space for surgeons. The Micor 700 will debut